Financial Shenanigans

Figures converted from Polish złoty (PLN) at historical period-end FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, multiples, days-sales-outstanding, and percentage changes are unitless and unchanged.

Financial Shenanigans

1. The Forensic Verdict

Forensic Risk Score: 46 / 100 — Elevated. Reported numbers are not obviously distorted, but the FY2025 income statement increasingly leans on items that an investor should not extrapolate. Roughly half of pretax profit comes from joint-venture equity-method accounting at Sierra Gorda — a line that includes a fresh USD 504 million impairment-test reversal plus USD 142 million of loan/share allowance reversals — while underlying operating "profit on sales" grew only 5.1%. Free cash flow has been negative in four of the last five years, receivables on the balance sheet jumped 55% on 3% revenue growth, and the group runs an explicit reverse-factoring (supplier-finance) program whose absolute outstanding balance is not disclosed in the public MD&A. Offsetting these signals: PwC has audited the parent since 2019 with no public qualification, balance-sheet leverage is genuinely modest (Net Debt / Adjusted EBITDA 0.76x), and the FY2023 big-bath impairment was triggered by an external commodity-price shock rather than an isolated reset. The grade would move down to Watch if the FY2025 audited financials disclose the absolute reverse-factoring balance and confirm DSO normalisation in 1H26; it would move up to High if FY2026 brings a third year of capex above operating cash flow with continued reliance on JV equity-method gains.

The headline cash-conversion gap is severe. Cumulative net income across FY2021–FY2025 totals roughly $3.2 billion; cumulative free cash flow over the same period is negative $0.7 billion. Operating cash flow alone exceeds net income (5y CFO/NI 1.56x), but capex has run at 13–17% of revenue while D&A is around 5–7%, so the maintenance-versus-growth-capex split is the right lens. The group is investing ahead of cash generation, paid for by debt issuance and by Sierra Gorda's USD 1+ billion of loan repayments since 2021. That is a defensible mining strategy — but it is not what reported earnings suggest.

Shenanigans Scorecard

2. Breeding Ground

State control plus rapid management turnover and a long-tenured auditor combine to create a moderate-risk environment. KGHM is not a perfect-quarter, never-miss compounder. Its earnings are commodity-driven and volatile by design, which actually reduces the temptation to smooth quarterly numbers. The risk vector here is different: politically-driven changes at the top, with a controlling shareholder whose objectives include national strategic policy as well as shareholder return.

The Polish State Treasury holds 31.79% of shares and the remaining 68.21% is free float held by Polish pension funds and international institutions. Between April 2025 and February 2026 the Supervisory Board carried out four major changes to the Management Board: dismissal of Vice President for International Assets (Iga Lis, April 2025), full re-appointment of the 12th-term board (June 2025), dismissal of CEO Andrzej Szydło and VP Corporate Affairs Piotr Stryczek (January 2026), and appointment of new CEO Remigiusz Paszkiewicz (February 2026). High-velocity board change is a structural feature of Polish state-owned enterprises and is not, by itself, evidence of accounting wrongdoing — but it raises the risk that strategic resets, asset-base re-evaluations, and impairment timing reflect political cycles rather than economic reality.

The compensation file is sober: variable pay capped at 100% of fixed pay, KPI-driven, no stock-option program. That structure does not push management toward aggressive accounting — but it also does not force discipline around capital allocation. The auditor selection policy enforces a maximum 10-year auditor tenure; PwC's mandate runs through FY2028, after which mandatory rotation must occur. Re-tender activity in 2027–2028 will be worth tracking.

3. Earnings Quality

Profit-on-sales — the closest proxy to operating profit — was effectively flat in FY2025 (+5.1%), but reported pretax grew +17.4% and net profit grew +28.5%. The wedge is almost entirely driven by joint-venture equity-method accounting at Sierra Gorda (KGHM's 55% Chilean copper-mine JV) and by the absence of last year's FX losses on intercompany loans.

In FY2025 the JV line alone ($808m) was 73% of the size of profit-on-sales ($1,102m). That JV line contains three discrete items the company itself disclosed in the MD&A: share in Sierra Gorda's profits +$448m, reversal of impairment loss on shares +$70m, and reversal of allowances for impairment of loans to the JV +$72m. The board separately announced a USD 504m fresh "initial determination" valuation on Sierra Gorda at year-end and a $167m reversal at the parent-only level on the Future 1 holding company that owns KGHM International. Stripping the impairment reversals — which by their nature should not recur — leaves a lower-quality FY2025 print.

Receivables jumped much faster than revenue

Total receivables on the consolidated balance sheet rose 55.1% ($609m to $1,082m) while revenue rose only 3.0%. DSO climbed to 32.1 days from 25.0 days. The MD&A's narrower "trade receivables" line — which excludes some intercompany and tax balances — rose 40.1% ($327m to $525m), and the company attributes most of that increase to "receivables measured at fair value" ($+177m of the +$150m trade-only net change), consistent with copper-price hedging revaluation rather than aggressive revenue recognition. That keeps the signal yellow rather than red — but it is the kind of jump that warrants the 1H26 watch list. If DSO fails to normalise and the FY2026 increase is concentrated in amortised-cost trade receivables (real customer bills with longer terms), the test moves to red.

Impairment cycle — three big baths in eleven years

The pattern is unambiguous: large write-downs cluster in commodity troughs (FY2015 — copper falling from USD 7,300/t to USD 4,500/t; FY2023 — copper retreat plus Polish PPE cost shock), and reversals appear on the way up. The FY2023 impairment was $695m on PPE and $333m on construction-in-progress for a total close to $1,028m. FY2025 carries a net reversal estimate of around $418m driven by Sierra Gorda's recovery. This is permitted by IAS 36 and is consistent with sector practice, but the back-and-forth shows that "reported earnings" through a cycle bear only loose relation to economic earnings. Five-year average net income FY2021–FY2025 is $674m; arithmetic mean reported net income is far less stable than free cash flow generation.

Hedge accounting and derivative liabilities

Derivative liabilities ballooned from $76m at FY2024 year-end to $854m at FY2025 year-end ($625m on silver hedges, $170m on copper). Most of the mark-to-market loss flows to the cash-flow hedge reserve in equity rather than the income statement until realisation. That is correct accounting under IFRS 9, but it does mean reported net income overstates the cash that will actually be received as those hedges roll off at below-market prices. Q1 2025 silver was USD 31.88/oz; Q4 2025 was USD 54.73/oz. KGHM is locked into older contracts.

4. Cash Flow Quality

The decisive forensic test — does CFO convert to FCF — KGHM fails by a wide margin. Five years of net income summing to $3.2 billion produced roughly $5.0 billion of CFO but capex of $5.7 billion, leaving cumulative free cash flow of negative $0.7 billion. The gap was funded by a mix of new debt issuance, JV repayments, and a draw-down of the cash balance.

CFO has been remarkably stable around $1.0–1.5 billion, even when reported net income has swung from -$0.9bn (FY2023) to +$1.9bn (FY2021). What has not been stable is capex. From FY2020's $0.7bn it has grown to $1.5bn in FY2025. Net of the FY2020 trough, capex has averaged $1.2bn and is now structurally above CFO.

Working-capital and the supplier-finance question

KGHM operates an explicit supplier-finance program in which banks pay suppliers early and KGHM repays the banks at the original 60-day commercial term. Its corporate website confirms the program; the FY2025 MD&A mentions only the change in trade payables financed under reverse factoring (a $196m reduction in FY2025; $245m reduction in FY2024) and the interest paid on those payables ($40m in FY2024, included in financing activities). The absolute outstanding balance at year-end is not in the MD&A. IFRS now requires disclosure of supplier-finance balances; the audited consolidated financial statements (March 2026 publication) should contain Note 12-level detail. Without the balance, an investor cannot tell whether CFO in earlier years was structurally inflated by program growth or whether the recent unwind reflects natural payment-cycle changes.

A reasonable interpretation: KGHM did expand the program in 2020–2022 to manage working capital through the COVID-era price spike and is now naturally winding it down. The current effect is a CFO headwind of around $200m–$245m per year. That is the right way around for a forensic analyst — the company is choosing transparency over CFO inflation in this period — but the historical question (was CFO 2020–2022 boosted?) cannot be settled from the MD&A alone.

Where FY2025 cash actually came from

Working-capital absorbed $650m of cash in FY2025 — receivables, inventory, and reverse-factoring unwind. Tax paid was $255m. Sierra Gorda separately repaid $336m of intercompany loan plus interest in 2025, which sits in investing cash flow rather than operating. That is the right classification under IFRS, but it does mean CFO understates the JV's economic contribution while the equity-method profit line in the income statement overstates it.

5. Metric Hygiene

KGHM's primary headline metric is Adjusted EBITDA — defined as profit-on-sales plus D&A and adjusted for impairment recognition and reversal on PPE in the core business. The definition is disclosed and reconciled in segment notes, but it has three properties an investor must price in:

The Adjusted EBITDA definition is unusual in two respects. First, it adjusts for impairment recognition and reversal on core PPE — that is internally consistent, but it means a year with large reversals (like FY2025) does not get a "boost" in Adjusted EBITDA from that line, while reported pretax does. Second, the metric is calculated excluding Sierra Gorda — sensible because the JV is equity-accounted, but it means the headline +21.5% Adjusted EBITDA growth and the +28.5% reported net profit growth measure different businesses. An investor reading only Adjusted EBITDA gets a clearer, slower-growing picture than one reading net profit.

The two lines that diverge most are Adjusted EBITDA (smooth and growing) and Net Income (volatile, depressed by impairments and FX). Pretax sits between them. This is honest accounting — but it is not a "single metric tells the whole story" company.

6. What to Underwrite Next

The forensic risk for KGHM is not that the FY2025 numbers are misleading; it is that they are mix-shifted. A higher share of profits is coming from joint-venture equity-method accounting and one-time impairment reversals, while the underlying Polish-mine and metallurgy business is growing only mid-single-digits with capex above operating cash flow. The position-sizing implication is to discount headline net income, anchor on Adjusted EBITDA ex-Sierra Gorda for sustainable run-rate, and treat the JV equity-method line as a separate optionality bucket that requires its own underwriting.

The forensic conclusion is that KGHM is a real, audited, regulated mining business with no evidence of revenue manipulation, no auditor qualification, and no regulator action — but with structurally negative free cash flow, a heavy reliance on a Chilean JV whose accounting is non-cash for most of the year, and an explicit supplier-finance program whose disclosure could be tighter. Treat reported net income as a directional indicator, anchor valuation on Adjusted-EBITDA-ex-Sierra-Gorda and the underlying capex cycle, and watch for the audited consolidated financials in late March 2026 for the absolute reverse-factoring balance and the receivables-by-measurement-category split.